The UK government has announced a major revamp of its efforts to get innovative new medicines and therapies through clinical development and to the market.
In this issue of Deep Dive we explore the ever present issues of market access and commercialisation, analysing recent changes in China, England and the US and asking how pharma can work with he
NHS England has announced a deal with AbbVie, Gilead, and Merck, Sharpe and Dohme (MSD) that aims to eliminate hepatitis C from the country - although it has had to drop a 2025 target
NICE has recommended that Akcea’s hereditary transthyretin-related amyloidosis (hATTR) treatment Tegsedi be made available on the NHS in England, ahead of a rival therapy from Alnylam.
We are pleased to invite you to the 4th Annual Antibody Drug Conjugates Summit: From Target to Therapeutics scheduled for May 15-16, 2019 in Vienna, Austria.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.